Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028865 | 1.00 | HTR2C (0.39) | HTR2CHSD17B10CHRNB4CHRNA3IDO1 | |
| SCHEMBL4050008 | 0.90 | PTGDR2 (0.40) | HTR2CHTR1A | |
| SCHEMBL4087954 | 0.88 | PTGDR2 (0.42) | HTR2C | |
| SCHEMBL15201663 | 0.84 | OPRL1 (0.38) | HTR2C | |
| SCHEMBL31188475 | 0.84 | OPRL1 (0.38) | HTR2C | |
| SCHEMBL11836887 | 0.84 | HTR2C (0.60) | HTR2CADRB2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL20133796 | 0.82 | ESR2 (0.35) | HTR2CPDPK1 | |
| SCHEMBL6940509 | 0.80 | CHRNB4 (0.50) | HTR2CCHRNB4CHRNA3IDO1PDPK1 | |
| SCHEMBL3425103 | 0.80 | CHRNB4 (0.50) | HTR2CCHRNB4CHRNA3IDO1PDPK1 | |
| SCHEMBL7845321 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-27 | — | — | US | disclosed |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2024-04-18 | — | — | US | disclosed |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020189540-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | 中外製薬株式会社 | 2020-09-24 | — | — | WO | disclosed |
| WO-2020189540-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | 中外製薬株式会社 | 2020-09-24 | — | — | WO | disclosed |
| CN-108774122-A | A method of the chloroform that no transition metal participates in is the carbonyl compound of carbonyl source into two fragrant first ketone compounds | 南京师范大学 | 2018-11-09 | — | — | CN | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-7820830-B2 | Process for the production of carboxanilides | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1951677-B1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080262242-A1 | Process For the Production of Carboxanilides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1951677-A1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | Syngeta Participations AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057140-A1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | HTR2C 2869/4885HSD17B10 1121/4885CHRNB4 3527/4885 |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | DDC, AADAT, TYR | HTR2C 2836/4885HSD17B10 1264/4885CHRNB4 4013/4885 |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | HTR2C 1038/4885HSD17B10 2103/4885CHRNB4 724/4885 |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | HTR2C 2869/4885HSD17B10 1121/4885CHRNB4 3527/4885 |
| US-20080262242-A1 | Process For the Production of Carboxanilides | FGFR2, FGFR4, CCKBR | HTR2C 1605/4885HSD17B10 3010/4885CHRNB4 2686/4885 |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | HTR2C 1038/4885HSD17B10 2103/4885CHRNB4 724/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | HTR2C 242/4885HSD17B10 1579/4885CHRNB4 423/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | HTR2C 2869/4885HSD17B10 1121/4885CHRNB4 3527/4885 |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | DDC, AADAT, TYR | HTR2C 2836/4885HSD17B10 1264/4885CHRNB4 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.